ТЕРИФЛУНОМИД – НОВЫЙ ТАБЛЕТИРОВАННЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ РЕМИТИРУЮЩЕГО РАССЕЯННОГО СКЛЕРОЗА (ОБЗОР)

СтатьяМЕД СОВЕТ. 2016; № 11: 57–61. DOI:10.21518/2079-701X-2016-11-57-61

Попова Е.В.^[1,2]

Бойко А.Н.^[1,2]

Давыдовская М.В.^[1,2]

ЗОЛОТОВА С.Н.^[2]

ХАЧАНОВА Н.В.^[1,2]

ШАРАНОВА С.Н.^[2]

^[1]«Российский национальный исследовательский медицинский университет имени Н.И.Пирогова»

^[2]Межокружное отделение рассеянного склероза (ГКБ №24 Департамента здравоохранения г. Москвы)

В данном обзоре представлены результаты экспериментальных и клинических исследований нового перорального препарата терифлуномид для патогенетического лечения рассеянного склероза (РС). Приведены механизм действия, данные клинических исследований II и III фаз по клинической эффективности, переносимости и безопасности. Обсуждается место терифлуномида в патогенетическом лечении РС.

рассеянный склероз

терифлуномид

Аборт самопроизвольный

Алопеция

Атрофия

Ацетаты

Безопасность

Белки

Боли

Больные

Ванны

Волосы

Врачи

Время

Глатирамера ацетат

Голова

Желудочно-кишечный тракт

Женщины

Здоровье

Интерфероны

Инфекции

Карповые

Кинез

Клиническое исследование

Конечности

Крысы

Легкие

Лефлуномид

Москва

Мужчины

Новорожденный

Обзор

Образование

Переводы

Пиримидины

Плазма

Плацебо

Причинная связь

Раны и травмы

Рецидив

Риск

Рост

Склероз

Слизистая оболочка

Тератогены

Торможение

Ферменты

Характер

Холестираминовая смола

Человек

Claussen MKorn T. Immune mechanisms of new therapeutic strategies in MS – Teriflunomide. Clinical Immunology. 2012;142(1):49-56. doi:10.1016/j.clim.2011.02.011..
DOI: 10.1016/j.clim.2011.02.011

O’Connor POh. An update of teriflunomide for treatment of multiple sclerosis. Therapeutics and Clinical Risk Management. 2013:177.doi:10.2147/tcrm.s30947..
DOI: 10.2147/tcrm.s30947

Bar-Or A. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. Experimental Neurology. 2014;262:57-65. doi:10.1016/j.expneurol.2014.06.005..
DOI: 10.1016/j.expneurol.2014.06.005

Garnock-Jones K. Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis. CNS Drugs. 2013; 27(12): 1103-1123. doi:10.1007/s40263-013-0118-2..
DOI: 10.1007/s40263-013-0118-2

O’Connor P, Li D, Freedman M et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894-900. doi:10.1212/01.wnl.0000203121.04509.31..
DOI: 10.1212/01.wnl.0000203121.04509.31

Confavreux C, Li D, Freedman M et al. Longterm follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Multiple Sclerosis Journal. 2012;18(9):1278-1289. doi:10.1177/1352458512436594..
DOI: 10.1177/1352458512436594

O’Connor P, Wolinsky J, Confavreux C et al. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2011;365(14):1293-1303. doi:10.1056/nejmoa1014656..
DOI: 10.1056/nejmoa1014656

Confavreux C, O’Connor P, Comi G et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, doubleblind, placebo-controlled, phase 3 trial. The Lancet Neurology. 2014;13(3):247-256. doi:10.1016/s1474-4422(13)70308-9..
DOI: 10.1016/s1474-4422(13)70308-9

Vermersch P, Czlonkowska A, Grimaldi L et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal. 2013;20(6):705-716. doi:10.1177/1352458513507821..
DOI: 10.1177/1352458513507821

Comi G, Freedman M, Kappos L et al. Pooled safety and tolerability data from four placebocontrolled teriflunomide studies and extensions. Multiple Sclerosis and Related Disorders. 2016;5:97-104. doi:10.1016/j.msard.2015.11.006..
DOI: 10.1016/j.msard.2015.11.006

HARRISON SBERGFELD W. Diffuse hair loss: Its triggers and management. Cleveland Clinic Journal of Medicine. 2009;76(6):361-367. doi:10.3949/ccjm.76a.08080..
DOI: 10.3949/ccjm.76a.08080

Freedman M. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Therapeutic Advances in Chronic Disease. 2013;4(5):192-205. doi:10.1177/2040622313492810..
DOI: 10.1177/2040622313492810

Dörr JPaul F. The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. Curr Treat Options Neurol. 2015;17(6). doi:10.1007/s11940-015-0354-5..
DOI: 10.1007/s11940-015-0354-5

Kieseier Benamor M. Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing– Remitting Multiple Sclerosis. Neurology and Therapy. 2014;3(2):133-138. doi:10.1007/s40120-014-0020-y..
DOI: 10.1007/s40120-014-0020-y

Utz K, Hoog J, Wentrup A et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Therapeutic Advances in Neurological Disorders. 2014;7(6):263-275. doi:10.1177/1756285614555335..
DOI: 10.1177/1756285614555335

Calabrese, M. et al., 2009. Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis. Arch Neurol, 66(9), pp.1144–1150.

Comi, G. et al., 2016. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Multiple Sclerosis and Related Disorders, 5, pp.97–104.

Confavreux, C. et al., 2014. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebocontrolled, phase 3 trial. The Lancet Neurology, 13(3), pp.247–256.

Harrison, S. & Bergfeld, W., 2009. Diffuse hair loss: Its triggers and management. Cleveland Clinic Journal of Medicine, 76(6), pp.361–367.

Kieseier, B.C. & Benamor, M., 2014. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurology and therapy, 3(2), pp.133–138.

Knecht, W. et al., 1996. Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. European journal of biochemistry / FEBS, 240(1), pp.292–301. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8925840.http://www.ncbi.nlm.nih.gov/pubmed/8925840

O ’connor, P. et al., 2011. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. Chilly Mazarin (H.B., P.T.) – both in France Stockholm (T.P.O.); Sanofi-Aventis N Engl J Med, 14365(6), pp.1293–303.

Popescu, V. et al., 2013. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry, 84(10), pp.1082–1091. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23524331.http://www.ncbi.nlm.nih.gov/pubmed/23524331

Riley, C. et al., 2012. Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques. Expert review of neurotherapeutics, 12(3), pp.323–33. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22364331.http://www.ncbi.nlm.nih.gov/pubmed/22364331

Sartori, A., Carle, D. & Freedman, M.S., 2014. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy, 15(7), pp.1019–1027. Available at: http://informahealthcare.com/doi/abs/10.1517/14656566.2014.902936n http://informahealthcare.com/doi/pdf/10.1517/14656566.2014.902936.http://informahealthcare.com/doi/abs/10.1517/14656566.2014.902936n

Sartori, A., Carle, D. & Freedman, M.S., 2014. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy, 15(7), pp.1019–1027. Available at: http://informahealthcare.com/doi/abs/10.1517/14656566.2014.902936n http://informahealthcare.com/doi/pdf/10.1517/14656566.2014.902936.http://informahealthcare.com/doi/pdf/10.1517/14656566.2014.902936

Sormani, M.P., Arnold, D.L. & De Stefano, N., 2014. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Annals of Neurology, 75(1), pp.43–49.

De Stefano, N. et al., 2014. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs, 28(2), pp.147–156.

Treadaway, K. et al., 2009. Factors that influence adherence with disease-modifying therapy in MS. Journal of Neurology, 256(4), pp.568–576.

Ullrich, A. et al., 2001. Recombinant expression of n-terminal truncated mutants of the membrane bound mouse, rat and human fl avoenzyme dihydroorotate dehydrogenase: A versatile tool to rate inhibitor eff ects? European Journal of Biochemistry, 268(6), pp.1861–1868. atology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum. 2007; 56(9):2896-2904.

Язык текста: Русский

ISSN: 2079-701X